Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis [Phase 1]
A Phase 1 imaging trial evaluating ABT 555 in relapsing forms of multiple sclerosis using [11C]-PBR28 PET has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® [Phase 4]
This Phase 4 study evaluated whether using a warm compress before daily Copaxone injections affects pain and tolerability in people with mul…
-
CLINICAL_TRIALS trial_result · 2017-02-01Clinical Trial Update: Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)
The document summarizes a completed Phase III trial evaluating ocrelizumab's impact on functional impairment in multiple sclerosis patients,…
-
CLINICAL_TRIALS research · 2017-02-01Clinical Trial Update: Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics
A multicenter validation protocol and reliability assessment for the Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in pe…
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
This completed clinical trial evaluated tolerability and quality of life in people who switched to the Avonex Pen (interferon beta-1a) for r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-01-26Clinical Trial Update: Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis [Phase 1]
Phase 1 trial evaluating the anti-inflammatory potential of alpha-lipoic acid in multiple sclerosis; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-01-25Clinical Trial Update: Vitamin D3 and the Stress-axis in MS [Phase 2]
A Phase 2 trial evaluating Vitamin D3's effect on the stress-axis in multiple sclerosis has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-01-23Clinical Trial Update: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate [Phase 4]
Phase 4 RESOunD trial on satisfaction after discontinuing dimethyl fumarate in multiple sclerosis. The study was terminated and results were…
-
FDA approval · 2017-01-23FDA Approved: DALFAMPRIDINE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for dalfampridine as a generic product manufactured by Aurobindo Pharma Limited.
-
FDA approval · 2017-01-23FDA Approved: DALFAMPRIDINE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s original application for dalfampridine (generic). This marks the approval of a generic dalfampridine pro…
-
FDA approval · 2017-01-19FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
The FDA approves Biogen's supplemental application for TECFIDERA (dimethyl fumarate), indicating an additional regulatory action related to …
-
CLINICAL_TRIALS trial_result · 2017-01-18Clinical Trial Update: Respiratory Function and Walking Capacity in Multiple Sclerosis [NA]
A completed clinical trial update examining respiratory function and walking capacity in people with multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-01-16Clinical Trial Update: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) [Phase 1]
A Phase 1 safety and tolerability study of PF-06342674 (RN168) in individuals with Multiple Sclerosis was terminated; results were posted on…
-
CLINICAL_TRIALS trial_result · 2017-01-10Clinical Trial Update: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis [Phase 2]
This update reports the Phase 2 clinical trial of Imilecleucel-T (Tcelna) for secondary progressive multiple sclerosis, which has completed …
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [Phase 3]
Phase 3 trial update reporting on the safety and efficacy of Natalizumab in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. [Phase 2]
The update notes the completion of a Phase 2 exploratory trial assessing dalfampridine (BIIB041) for walking ability and balance in people w…
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: Safety Study of BIIB033 in Subjects With Multiple Sclerosis [Phase 1]
A Phase 1 safety study of Opicinumab (BIIB033) in subjects with Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis has completed.
-
CLINICAL_TRIALS research · 2016-12-29Clinical Trial Update: Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort
This study analyzes baseline characteristics and identifies predictors of disease progression in an Egyptian cohort of patients with multipl…
-
CLINICAL_TRIALS withdrawal · 2016-12-29Clinical Trial Update: Alternative Treatment Paradigm for Natalizumab Trial [Phase 2]
A Phase 2 trial evaluating natalizumab for multiple sclerosis has been withdrawn. The sponsor indicates the study is no longer active.
-
CLINICAL_TRIALS research · 2016-12-23Clinical Trial Update: Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction
A clinical trial update discusses subclinical cardiovascular dysfunction in people with multiple sclerosis. The current status of the trial …
-
FDA approval · 2016-12-22FDA Approved: LIORESAL (BACLOFEN) — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for LIORESAL (baclofen) submitted by Amneal Pharmaceuticals LLC.
-
CLINICAL_TRIALS research · 2016-12-14Clinical Trial Update: Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/)
This update describes a clinical trial evaluating potential gadolinium accumulation from two MRI contrast agents, Dotarem and Multihance, in…
-
CLINICAL_TRIALS trial_result · 2016-12-08Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes [Phase 1]
This Phase 1 study reports pharmacokinetics, safety and tolerability of single doses of Opicinumab (BIIB033) produced by two manufacturing p…
-
CLINICAL_TRIALS research · 2016-12-08Clinical Trial Update: Self-Management Program Based on Physical Exercises in People With Multiple Sclerosis [NA]
Clinical trial update evaluating a self-management program based on physical exercises for people with Multiple Sclerosis; no current status…
-
CLINICAL_TRIALS research · 2016-12-07Clinical Trial Update: Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients [NA]
Completed clinical study investigating a method to selectively detect CD8+ myelin-specific T cells in the blood of multiple sclerosis patien…